Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial
Authors:
- 9 October 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (1) , 84-91
Abstract
To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX. This randomized, placebo-controlled non-inferiority study involved patients with severe active RA [28-joint DAS (DAS28) >5.1] who had initiated tocilizumab + MTX at the study start. Patients received open-label tocilizumab (8 mg/kg i.v. every 4 weeks) and open-label MTX. At week 24, patients achieving good/moderate EULAR response were randomized to group A (double-blind MTX taper) or group B (double-blind MTX maintenance); both arms continued open-label tocilizumab. Primary analysis was the proportion of patients maintaining good/moderate EULAR response from week 24 to 60. The study stopped early due to low recruitment, although the predetermined non-inferiority criteria were still met; 427 patients were enrolled to the open-label phase at week 0. At week 24, EULAR good/moderate response was achieved in 272 individuals (64.4%) who were randomized, 136 in each arm (36% withdrew/were not eligible). Additionally, 45.0% achieved DAS28 ⩽3.2, 33.5% achieved remission (DAS28 0.9, the pre-determined criteria for non-inferiority was fulfilled despite reduced recruitment. Safety analysis revealed no unexpected tocilizumab safety signals. Tapering MTX in patients with RA receiving tocilizumab was non-inferior to continuing stable MTX in maintaining a good/moderate EULAR response. There were no unexpected safety signals; tocilizumab and MTX therapy was generally well tolerated in both groups. Trial registration number: EudraCT 2011-005260-20Keywords
This publication has 20 references indexed in Scilit:
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Annals of the Rheumatic Diseases, 2013
- Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2011
- Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritisCurrent Opinion in Rheumatology, 2010
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals of the Rheumatic Diseases, 2010
- Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritisJournal of Psychosomatic Research, 2009
- Rheumatoid Arthritis A Model of Systemic Inflammation Driving AtherosclerosisCirculation Journal, 2009
- The efficacy of inhibiting tumour necrosis factor and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisonsRheumatology, 2007
- Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease‐modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Functional disability in rheumatoid arthritis patients compared with a community population in FinlandArthritis & Rheumatism, 2003
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994